.; .. ,p
`
`JJfei~ chemicals
`r Bl Reagents
`
`fo~ Life Science Researcli
`
`2004~2005
`
`Cell Cu lture
`
`Cell Signaling
`
`Equipment
`
`Molecular Biology
`
`Proteomics
`
`

`

`To Place An Order
`
`Telephone
`
`Sigma-Aldrich Ordering and Customer Service
`To place an order or to inquire about an existing order:
`800-325-3010
`sigma-aldrich.com/order
`800-325-5052
`For instructions on opening a new
`account, see page 4
`
`Internet
`FAX
`
`Technical Service
`To discuss applications or product-specific questions:
`800-325-5832
`Telephone
`sigma-aldrich.com/techinfo
`Internet
`
`Development and Manufacturing Scale Inquiries
`Contact Sigma-Aldrich Fine Chemicals for your large scale needs:
`800-336-9719
`Telephone
`sigma-aldrich,com/safc
`Internet
`800-368-4661
`FAX
`
`Bid Requests/Quotation
`FAX
`
`800-554-6541
`
`Electronic Commerce Inquiries
`877-856-5586
`Web site Help Desk
`Web site Customer Support 800-286-2635
`EDI & Business
`Integration Projects
`
`800-325-4940
`
`To Make a Payment
`Payers East of the Mississippi remit to:
`P.O. Box 932594
`Atlanta, GA 31193-2594
`Payers West of the Mississippi remit to:
`P.O. Box 951524
`Dallas, D< 75395-1524
`
`The Sigma Creed
`
`• Let No Non-Profit research organization anywhere in the world, suffer for la,ck
`of Sigma Reagents.
`
`• Let No One have cause to say a Sigma Product was misrepresented.
`
`• Let No One have cause to say that Sigma was not More Than fair, friendly,
`reasonable, and cooperative in every way.
`
`• Let No One have cause to say that a Sigma Product was not absolutely the
`finest available anywhere.
`• Make Everyone feel that doing business with Sigma is a revelation and a
`pleasure! Even if you can't pay.
`
`• As Long as we have the funds, no legitimate call for help will be disregarded.
`THE ABOVE (REED WAS f\JBIJ5HED MANY YEARS AGO W'HEN RESEARCH WAS GENEllAI.LY CARRl[D OUT IN "RESEARCH ORGANIZAOON'i." THE CURRENT TREND l'l'ITIIIN
`l'REPAMTORYSCHOOLS,HOSPITALS,ANOCUNICSTODO"RESEARCH" A5ATEACHINGfUNCT10NORA5APAIIT·TIMEDIERCISE,HASCREATEDAD[tMNDFOR
`51GMA-fiNA.NCINGNOT.'ffiNDEDTOBECOVEREDBYTHJS(RHD. HOWEYER,SPEC~ICl~IRlfiAREIIMTID,
`
`Sigma-Aldrich
`Service in:
`
`Argentina
`Australia
`Austria
`Belgium
`Brazil
`Canada
`China
`Czech Republik
`Denmark
`Finland
`France
`Germany
`Greece
`Hungary
`India
`Ireland
`Israel
`Italy
`Japan
`Korea
`Malaysia
`Mexico
`The Netherlands
`Norway
`Poland
`Portugal
`Russia
`Singapore
`South Africa
`Spain
`Sweden
`Switzerland
`United Kingdom
`USA
`
`©2004 Sigma-Aldrich Co. Reproduction forbidden without permission Sigma ilnd ,_~ me registered trademarks of Sigma-Aldrich Biotechnology LP
`
`' SIGMA
`
`I off and adhere to computer monitor frame.
`
`j
`j JANUARY 2005
`5 M T W T F 5
`5 6 7 J
`~6 ~1 25 26 27 28 29
`j
`J FEBRUARY 2005
`SMTWTFS
`1 2 3 4 5
`6 7 8 9101112
`13 14 15 16 17 18 19
`~~ ~J 22 23 24 25 26
`! MARCH 2005
`j
`5 M T W T F 5
` 1~ n l~
`1 2 3 4 5
`8
`5 1
`1\ ,74 1
`~~ ~~ ~ ~6 ~125 26
`I
`j
`APRIL 2005
`SMTWTFS
`5 6 7 J ~
`
`4
`3
`2
`9 10 11 12 13 14 15
`16 17 18 19 20 21 22
`
`96
`
`4
`3
`10 11 12 13 14 15 16
`17 18 19 20 21 22 23
`24 25 26 27 28 29 30
`j
`j
`MAY2005
`5 M T W T F S
`1234567
`8 9 10 11 12 13 14
`15 16 17181920 21
`
`~~ ~6 ~1 25 26 27 28
`I
`j
`JUNE 2006
`SMTWTFS
`1 2 3 4
`5 6
`7 8 9 10 11
`12 13 14 15 16 17 18
`19 20 21 22 23 24 25
`26 27 28 29 30
`r
`1
`JUI.Y 2005
`S M T W T F 5
`34567 J~
`10 111213 1415 16
`17 18 19 20 21 22 23
`
`~1 25 26 27 28 29 30
`j AUGUST 2005
`j
`S M T W T F 5
`1 2 3 4 5 6
`
`17,, ,°s i96 ~y 1i l~ ~~
`21 22 23 24 25 26 27
`28 29 30 31
`! SEPTEMBER 2005 I
`5 M T W T F S
`
`4567 J~ ,30
`11 12 13 14 15 16 17
`18 19 20 21 22 23 24
`25 26 27 28 29 30
`I OCTOBER 2005
`j
`5 M T W T F S
`5 6 1 A
`4
`2 3
`9 10 11 12 13 14 15
`16 17 18 19 20 21 22
`~6 ~1 25 26 27 28 29
`/ NOVEMBER 2005 I
`S M T W T F S
`67J~,301~,S2
`U 14 15 16 17 18 19
`
`~~ u ~~ ~6 24 25 26
`
`1 DECEMBER 2005 r
`5 M T W T F 5
`1 2 3
`6 7 8 9 10
`5
`4
`11 12 13 14 15 16 17
`18 19 20 21 22 23 24
`25 26 27 28 29 30 31
`
`JANUARY 2004
`j
`MTWTFS
`1 2 3
`5 6 7 8 9 10
`12 13 14 15 16 17
`19 20 21 22 23 24
`26 27 28 29 30 -31
`j
`FEBRUARY 2004
`MTWTFS
`2345 67
`9 10 11 12 13 14
`16 17 18 19 20 21
`2-3 24 25 26 27 28
`
`j
`MARCH2004
`M T W T F S
`1 2 3 4 5 6
`8 9 10 11 12 13
`15 16 17 18 19 20
`22 23 24 25 26 27
`29 30 31
`APRIL2004
`j
`MTWTFS
`1 2 3
`5 6
`7 8 9 10
`12 13 1"4 15 16 17
`19 20 21 22 23 24
`26 27 28 l9 30
`j
`MAY2004
`M T W T F S
`3 4 5 6 7 J
`lY lJ 1~ JJ ;1 ;~
`~1 25 26 27 28 29
`j
`JUNE 2004
`M T W T F S
`1 2 3 4 5
`7 8 9 101112
`14 15 16 17 18 19
`!1 22 23 24 25 26
`!8 29 30
`I
`JULY 2004
`\IITWTFS
`
`567~~,30
`2 13 14 15 16 17
`9 20 21 2.2 23 24
`IG 27 28 29 30 31
`j
`~UGUST 2004
`,1TWTFS
`l 3 4 S 6 7
`3 10 11 12 13 14
`6 17 18 19 20 21
`
`6 fl 25 26 27 28
`
`PTEMBER 2004 j
`~TWTFS
`
`1 ,J~1~1~
`3 14 15 16 17 18
`D 21 22 23 24 25
`1 28 29 30
`j
`CTOBER 2004
`1TWTFS
`
`. 557 J~
`I 12 13 14 15 16
`3 19 20 21 22 23
`i 26 27 28 l9 30
`
`•VEMBER 2004 j
`I TWTFS
`2 3 4 5 6
` lY lJ l~ 16
`; 1
`i j~ 24 2S 26 27
`j
`CEMBER 2004
`T W T F S
`1 2 3 4
`7 8 9 10 11
`
`~1 g 1~ ll lt
`
`28 29 30 31
`
`96
`
`1rch by product
`:As• number,
`ii structures and
`:tures.
`
`

`

`Jharmaceutical components ranging from
`31 and transgenic sources, and bio-organics
`"gents for biopharmaceutical companies
`have developed over 36,000 processes
`of our biopharmaceutical specialties include
`on, chromatography, media development and
`ia manufacturing, serum free and animal
`hesis, and lyophilization.
`
`1P manufacture of materials required for cell
`, Missouri facility and 124,000 sq. ft. Irvine,
`Jid media and other aseptic liquid solutions
`s of expertise are animal-free media and
`1s to optimize cell growth and productivity.
`I and vertical ribbon blender technology are
`
`Alphabetical List
`of Compounds
`All of our products, except for equipment,
`are t,ow listed in this section. The majorit~ of
`preducts, and all cross-references, are listed
`alphabetically. Some products have been
`placed in special sections, e.g., PCR reagents
`and kits, but will have cross-references in the
`expected alphabetical location.
`
`r for the full range of biological buffers
`I more. We manufacture in lot sizes up to
`1s. The buffers facility in St. Louis, Missouri
`1 throughput and has large-scale
`1r biological buffers are used in cell culture
`J, and formulation.
`
`1 St. Louis, Missouri designed for the bio-
`d APl's. The facility features fully validated
`essing, USP water, process control, HEPA
`systems. Products produced here include
`::>hydrates, and other custom processes.
`
`1uantity orders and custom development
`ing facilities at sigma-aldrich.com/tours
`
`1 • www.sigma-aldrich.com/techinfo
`
`

`

`(Continuation of)
`Monoclonal Anti-Calcineurin (P-Subunit)
`
`Application(s)
`• •• , 1 :3000 using a rat brain extract
`lmmunoblotting~ •
`lmmunohistochemistry (formalin-fixed, paraffin-embedded
`sections) • suitable using neurons in human myenteric and
`prostatic ganglia
`• suitable
`Indirect ELISA
`lsotype, .••• & • • • • • • • • , . . . . . . _ • • • • • lqM
`250 µg
`204.60
`Calcineurin autoinhibitory frag-
`C 3937 ment
`lle-Thr-Ser-Phe-Glu-Glu-Ala-lys-Gly-leu-Asp-Arg-lle-
`@:£l
`Asn-Glu-Arg-Met-Pro-Pro-Arg-Arg-Asp-Ala-Met-Pro
`[148067-21-4] C124H2osNag039S2 FW 2930
`min. 90% (HPLC)
`Ref.: 1 Hashimoto. Y., et al., J. Biol. Chem 265, 1924 (1.990)
`
`Calcineurin substrate See: Protein Kinase Related Peptides Page 1718
`Calciol See: Cholecalciferol Page 477
`
`I
`I I.I
`
`iij u
`
`C 2355
`@:£l
`
`T 1284
`@:£]
`
`0.1 ml
`
`50 µg
`
`236.40
`
`63 .00
`
`168.50
`
`Anti-Calcitonin
`antibody produced in rabbit
`Whole antiserum, Lyophilized powder
`Ref.: 1 Hokfelt, T et al., Experientia Suppl. 56, 154 (1987)
`2. Sud hot, T.C. . Nature 375. 645 (1995)
`Calcitonin eel
`Thyrocalcitonin Eel; Cys-Ser-Asn-
`leu-Ser-Thr-Cys-Val-leu-Gly-lys-leu-Ser-Gln-Glu-
`leu-His-lys-leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asp-Val(cid:173)
`Gly-Ala-Gly-Thr-Pro-NH2 [Disulfide bridge: 1-7]
`[57074-02-5] C145H241N4a0,1S2 FW 3414
`min. 97% (HPLC)
`Hypocalcemic hormone produced by the parafollicu(cid:173)
`lar C cells of the thyroid or by the ultimobranchial
`bodies of nonmammalian vertebrates. Decreases
`blood calcium and phosphate due to inhibition of
`resorption by osteoblasts and osteocytes
`A 32 amino acid polypeptide, 8 of which are
`conserved across all species,
`Ref.: 1- Tenenhouse, A_, et aL, Proc. Nat Acad. Sci. USA 53,
`818 (1965)
`2. Brewer, H,B., et al., J, Biol. Chem, 2454, 4232 (1970)
`3, Schlueter, et al,, Endocrinology 81, 854 (1967)
`4. Farley, J, R, et al., Endocrinology 123, 159 (1988)
`Acetyl-[Asn30
`, Tyr32]-Calcitonin
`500 µg
`A 0597
`fragment 8-32 trifluoroace-
`tate salt
`@:£]
`AC 187; Ac-Val-leu-Gly-lys-leu-Ser-Gln-Glu-leu(cid:173)
`His-lys-leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-Gly-Ser(cid:173)
`Asn-Thr-Tyr-NH2
`[157804-77-2] CmH2osN310,o FW 2890
`min. 97% (HPLC)
`Potent and selective antagonist of amylin-induced
`hyperglycaemia and hyperlactoemia.
`Ref.: 1 Lutz, TA., et al ,, Amylin receptors mediate the
`anorectic action of salmon calcitonin (sen Peptides 21, 233
`(2000)
`
`0.2 ml
`
`DRY ICE •
`
`Anti-Calcitonin Gene Related
`C 8198
`Peptide (CGRP)
`antibody produced in rabbit
`~
`Whole antiserum, liquid
`lmmunogen: CGRP-KlH
`Species reactivity: rat
`contains 15 mM sodium azide
`App/ication(s)
`, • 1 :5,000
`Radioimmunoassay,
`1: 10,000
`• •
`Dot blot • • •
`lmmunohistochemistry •• 1 :8,000 using 4% paraformalde-
`hyde perfusion-fixed, frozen sections of rat brain
`Monoclonal Anti-Calcitonin Gene-Related Peptide
`Anti-CG RP
`lsotype ••••••• , ••••. , •
`
`• • , • _ •• . , ,
`
`lgGt
`
`350
`
`• Shipping information - page 6 • Larger quantities - see page 16
`
`Alphabetical List of Products
`
`Monoclonal Anti-Calcitonin
`Gene-Related Peptide
`antibody produced in mouse
`Clone CDS, Purified immunoglobulin, Buffered
`aqueous solution
`lmmunogen: peptide corresponding to the (-terminal
`of rat a-calcitonin gene-related peptite (CGRP).
`Solution at approximately 1 00 µg/ml in 20 mM
`sodium phosphate buffer containing 0.01 % sodium
`azide.
`Species reactivity: human, guinea pig
`Application(s)
`Indirect immunofluorescence~ •
`incubation at 4°(
`tmmunohistochemistry (formalin-fixed, paraffin-embedded
`sections).
`1 :200-1 :1,000 using ovenight incubation at 4°C
`a~d sections that h;1ve beitn protease-digested or processed by
`high temperature aritJgen retrieval
`suitable
`lmmunocytochemistry,
`Ref.: 1, Amara. S G •. et al . Science 229, 1094-1097 (1985)
`100 µl
`250.00
`Monoclonal Anti-Calcitonin
`Gene-Related Peptide
`antibody produced in mouse
`approx. 2 mg/ml, Clone 4901, Purified immuno(cid:173)
`globulin, Buffered aqueous solution
`lmmunogen: rat a-CGRP peptide. The epitope
`recognized by the antibody resides within the
`(-terminal ten amino acids of rat a-CGRP.
`Cross-reacts with human and dog a- and ~-CGRP,
`Solution in 0.01 M phosphate buffered saline, pH 7.4,
`containing 15 mM sodium azide.
`Species reactivity: rat
`Application(s)
`Indirect ELISA
`Rad101mmunoassay.
`lmmunocytochemistry,
`Neutralization.
`Calcitonin Gene Related Peptide 0.1 mg
`fragment 8-37 human
`O 5 mg
`a-CGRP 8-37; FBHuman; Val-Thr-
`1 mg
`His-Arg-leu-Ala-Gly-leu-leu-Ser(cid:173)
`Arg-Ser-Gly-Gly-Val-Val-lys-Asn-Asn-Phe-Val-Pro(cid:173)
`Thr-Asn-Val-Gly-Ser-lys-Ala-Phe-NH2
`[779977-68-7] C1a9H230N4403e FW 3125
`min. 97% (HPLC), powder
`Selective competitive antagonist at CGRP receptors
`but not at calcitonin receptors.
`Peptide content approx. 70%
`Ref.: 1. Chiba, T., et al., Calcitonin gene-related peptide
`receptor antagonist human CGRP-(8-37) Am J. Physio/ 256,
`[331 (1989)
`2 Han, S.P , et al , Inhibition of periarterial nerve stimulation(cid:173)
`induced vasodilation of the mesenteric arterial bed by CGRP (8-
`37) and CGRP receptor desensitization Biochem. Biophys Res.
`Comm, 168, 786-791 (1990)
`3. Escott, K,J., and Brain, S.D., Effect of a cakitonin gene(cid:173)
`related peptide antagonist (CGRPS-37) on skin vasodilatation
`and oedema induced by stimulation of the rat saphenous nerve
`329.50 1 ___ __,;B"'r . .:;J,'-'P.;,;ha::.:;rm.;,;a::;;<.::;o/_ 1:...;1::,0,...;,7.:.;72:..•7:.;.7-=-6-'-'(1-=.99::..:3"-) _____ _
`Calcitonin Gene Related Peptide 0.1 mg
`70.90
`250 µg
`155.00
`human
`0,5 mg
`260 00
`CGRP-I; a-CGRP; Ala-Cys-Asp-
`Thr-Ala-Thr-Cys-Val-Thr-His-Arg(cid:173)
`leu-Ala-Gly-leu-leu-Ser-Arg-Ser-Gly-Gly-Val-Val-lys(cid:173)
`Asn-Asn-Phe-Val-Pro-Thr-Asn-Val-Gly-Ser-lys-Ala-
`Phe-NH2) [Disulfide Bridge: 27]
`[90954-53-3] C153H251Ns,049S2 FW 3789
`min. 95% (HPLC), powder
`Potent, long-lasting vasodilator; activation of CGRP
`receptors on pancreatic ~-cells increases plasma levels
`of pancreatic enzymes.
`P-Calcitonin Gene Related Pep-
`C 1044
`tide human
`p-CGRP; CGRP-II; Ala-Cys-Asn(cid:173)
`@:£l
`Thr-Ala-Thr-Cys-Val-Thr-His-Arg-leu-Ala-Gly-leu(cid:173)
`leu-Ser-Arg-Ser-Gly-Gly-Met-Val-lys-Ser-Asn-Phe-
`
`C 9487
`@:£]
`DRY ICE
`@!I>
`
`C 7113
`@:£]
`DRY ICE
`@!I>
`
`C 2806
`@:£l
`
`C 0167
`@:£l
`
`100 µl
`
`"· :1
`
`1 :500 using overnight
`
`O 5 µg/ml using rat a-CGRP
`• . suitable
`•
`suitable
`• •• suitable
`50 50
`168.50
`294.00
`
`0.1 mg
`1 mg
`
`81.20
`405.00
`
`www_.sigma-ald,ri
`
`c 0292
`0ffi
`
`Val-Pro-Thr-Asn-Val-Gly-Ser-L
`Ode Bridge: 2-71
`(98824-26-11 Ct52HmN51o
`min. 97 % (HPLC)
`Potent hypotensive agen and
`Peptide content approx. 70%
`Raf,: 1 Slec-nb\Jrgh, P.H., Cl al., FE
`2. Stoenburgh. P.H., e1 al, FEBS La
`Calcitonin Gene Related Peptid
`rat
`·
`CGRP-I; a-CGRP; Ser-Cys-Asn(cid:173)
`Thr-Ala-Thr-Cys-Val-Thr-Hls-Ar
`leu-Ala-Gly•leu-Leu•Ser-Arg .
`Asp-Asn-Phe-Val-Pro-Thr•Asn.
`Phe-NH 2) [Disulfide Bridge: 27
`[96827-03-1] C152HmN500
`min. 97% (HPlCJ, powder
`Potent, long-lasting vasodilator
`recep1ors on pancreatic P-cells ii
`ocreatic- e mes.
`of
`Calcitonin human
`T 3535
`Thyrocalcitonin; hCT; Calcitoni~
`~ human reduced cyclic (1 (cid:157) 7)(cid:173)
`disulfide; Calcitonin M, human 1
`carcinoma; Cys-Gly-Asn-leu-Ser
`Thr-Cys-Met-leu-Gly-Thr-Tyr-TH
`l ys-Phe-H is-Thr-Phe-Pro-G In-Th
`Ala-Pro-NH2 [Disulfide Bridge: 1
`121215-62-Jl c,,, H1>6N.00 4
`min, 97 % (HPlC), powder
`Hypoealcemlc hormone produ
`lar C cells of the thyroid or by
`bodies of nonmammalian verte,
`blood calcium ~nd phosphate d
`resorption by osteoblasts ~ nd d
`A 32 amino acid polypeptide, ~
`con~eNed across all spede5.
`H-(Cys-Gly•Asn-Leu-Ser-Thr-C
`Thr-Tyr-Thr-Gln-Asp-Phe-Asn•l
`Pro-Gln-Thr-Ala-lle-Gly•Val-Gly(cid:173)
`R.of.: 1, Tenenhouie. A. et al .• Proc.
`818 (1965)
`2. 8re,~r, H.B. et ol, J. 8/ol. Chem
`3. Schlueter, et al., Endouino/ogy 8
`4. Failey, J. R., et al,, fndouir,qlogy
`S: 22-24/25
`
`Calcitonin porcine
`T 0158
`Thyrocalcitonin; Cys-Ser-Asn-le1
`~ Ser-Thr-Cys-Val-leu-Ser-Ala-Tyr!
`Asn-Asn-Phe-His-Arg-Phe-Ser-G
`Pro-Glu-Thr-Pro-NH2 [Disulfide I
`[/2327-44-7] C1s9H232N4504s1
`i
`min. 97% (HPLC)
`Hypocalcemic hormone product
`lar C cells of the thyroid or by I
`bodies of nonmammalian vertei
`blood calcium and phosphate d
`resorption by osteoblasts and ol
`A 32 amino acid polypeptide, 8
`conserved across all species.
`'
`Ref.: 1. Tenenhouse, A, et al., Proc. 1
`818 (1965)
`2. Brewer, H.B., et al, J. Biol. Chem 1
`3. Schlueter, et al, Endocril>ology 81
`4, Farley. J. R., et al., Endoctfnofogy
`Calcitonin rat
`T 0283
`Thyrocalcitonin; Cys-Gly-Asn-
`~ leu-Ser-Thr-Cys-Met-leu-Gly(cid:173)
`Thr-Tyr-Thr-Gln-Asp-leu-Asn(cid:173)
`lys-Phe-H is-Th r-Phe-Pro-G In-Th
`Ala-Pro-NHi )Disulfide Bridge: 1
`[ 11 118-25-5) C14eH22sN4o045
`min. 95% (HPLC), powder
`Hypocalcemic hormone produc
`lar C cells of the thyroid or by
`
`e I •
`
`•
`
`•
`
`e I,.
`
`

`

`·-··- -~ - - . . . . - __ . ~~-~-----~- -~
`
`us$
`
`Val-Pro-Thr-Asn-Val-Gly-Ser-Lys-Ala-Phe-NH 2 [Disul-
`fide Bridge: 2-7]
`[98824-26-7] C162H267N51 O4sSa FW 3793
`min. 97% (HPLC)
`Potent hypotensive agent and vasodilator.
`Peptide content approx. 70%
`Ref.: 1 Steenburgh, PH, et al, FEBS Lett. 183,403 (1985)
`2, Steenburgh, PH., et al, FEBS Lett. 209, 97 (1~_6)__
`
`T 3535
`@:§]
`
`50 µg
`250 µg
`0,5 mg
`1 mg
`
`73 ,00
`205,00
`314.00
`523.00
`
`C 1000 min. 99% (titration), powder 100 g
`Color, ,
`. .
`• while 500 g
`2.5 kg
`
`16.60
`56.40
`223.00
`
`bodies of nonmammalian vertebrates. Decreases
`blood calcium and phosphate due to inhibition of
`resorption by osteoblasts and osteocytes
`A 32 amino acid polypeptide, 8 of which are
`conserved across all species.
`Ref.: 1. Tenenhouse, A., et al., Proc. Nat. Acad Sci. USA 53,
`818 (1965)
`2. Brewer, H B. et al, 1 Biol. Chem 2454, 4232 (1970)
`3. Schlueter, et al., Endocrinology 81, 854 (1967)
`4 Farley, J R., et al., Endocrinology 123, 159 (1988)
`Calcitonin Gene Related Peptide 0. 1 mg
`83 .80
`rat
`183 .501 - - - - - -- - - - - - - - - - - - - ' - - · ·
`250µg
`co292
`@:§]
`CGRP-I; a-CGRP; Ser-Cys-Asn-
`0.5 mg
`307,50
`Calcitonin salmon
`50 µg
`40.20
`Thyrocalcitonin; Cys-Ser-Asn-
`Thr-Ala-Thr-Cys-Val-Thr-His-Arg-
`T 3660
`250 µg
`146 50
`Leu-Ala-Gly-Leu-Leu-Ser-Arg-Ser-Gly-Gly-Val-Val-Lys- ~ Leu-Ser-Thr-Cys-Val-Leu-Gly-Lys-
`0.5 mg
`230.50
`Asp-Asn-Phe-Val-Pro-Thr-Asn-Val-Gly-Ser-Glu-Ala-
`Leu-Ser-Gln-Glu-Leu-His-Lys-
`1 mg
`322.00
`Phe-NH2) [Disulfide Bridge: 27]
`Leu-Gln-Thr-Tyr-Pro-Arg-Thr-
`[96827-03-7] C162H262 N50Os2S2 FW 3806
`Asn-Thr-Gly-Ser-Gly-Thr-Pro-NH2 [Disulfide Bridge: 1-
`min. 97% (HPLC), powder
`7]
`Potent, long-lasting vasodilator; activation of CGRP
`[47931-85-1] C14sH240N44O48S2 FW 3431
`receptors on pancreatic P-cells increases plasma levels
`min. 97% (HPLC), powder
`of pancreatic enzymes.
`Hypocalcemic hormone produced by the parafollicu(cid:173)
`lar C cells of the thyroid or by the ultimobranchial
`Calcitonin human
`bodies of nonmammalian vertebrates. Decreases
`Thyrocalcitonin; hCT; Calcitonin,
`blood calcium and phosphate due to inhibition of
`human reduced cyclic (1---.7)(cid:173)
`resorption by osteoblasts and osteocytes.
`disulfide; Calcitonin M, human C
`A 32 amino acid polypeptide, 8 of which are
`carcinoma; Cys-Gly-Asn-Leu-Ser(cid:173)
`conserved across all species.
`Thr-Cys-Met-leu-Gly-Thr-Tyr-Thr-Gln-Asp-Phe-Asn(cid:173)
`H-(Cys-Ser-Asn-Leu-Ser-Thr-Cyslc,c1 -Val-Leu-Gly-lys(cid:173)
`Lys-Phe-His-Thr-Phe-Pro-Gln-Thr-Ala-lle-Gly-Val-Gly(cid:173)
`Leu-Ser-G In-GI u-Leu-H is-L ys-Leu-G In-Th r-T yr-Pro(cid:173)
`Ala-Pro-NH2 [Disulfide Bridge: 1-7]
`Arg-Th r-Asn-Th r-G ly-Ser-Gly-Thr -Pro-N H2
`[27275-62-3] C1s1H226N4oO4sSa FW 3417
`Ref.: 1. Tenenhouse, A, et al, Proc. Nat. Acad. Sci. USA 53,
`min. 97% (HPLC), powder
`818 (1965)
`Hypocalcemic hormone produced by the parafollicu(cid:173)
`2. Brewer, H.B., et al , 1. Biol. Chem. 2454, 4232 (1970)
`lar C cells of the thyroid or by the ultimobranchial
`3 Schlueter, et al, Endocrinology 81,854 (1967)
`bodies of nonmammalian vertebrates. Decreases
`4 Farley, J, R, et al., Endocrinology 123, 159 (1988)
`blood calcium and phosphate due to inhibition of
`5: 22-24/25
`resorption by osteoblasts and osteocytes.
`catcitriol See: 1o.2S·Oihydr0l<)'\'llamin D3 Paae 662
`A 32 amino acid polypeptide, 8 of which are
`Calcium acetate hydrate
`conserved across all species.
`(CH3COO),Ca • aq FW 158.2
`[62-54-4]
`H-(Cys-Gly-Asn-Leu-Ser-Thr-Cys)cyc1 -Met-leu-Gly(cid:173)
`R: 36/37/38 5: 26-36
`Thr-Tyr-Th r-G I n-Asp-Phe-Asn-L ys-Phe-H is-Thr-Phe(cid:173)
`Pro-G In-Th r-Ala-lle-G ly-Va l-G ly-Ala-Pro-N H2
`Ref.: 1 Tenenhouse, A, et al , Proc. Nat Acad. Sci USA 53,
`818 (1965)
`2 Brewer, H B , et aL, 1. Biol. Chem_ 2454, 4232 (1970)
`3 Schlueter, et al., Endocrinology 81,854 (1967)
`4 Farley, J, R, et al., Endocrinology 123, 159 (1988)
`S: 22-24/25
`
`C 4705
`
`100 g
`500 g
`
`39.00
`67. 70
`
`SigmaUltra, approx. 99 % (ti•
`tration)
`Insoluble matter.
`<0, 1 %
`Phosphorus (P),
`Calcitonin porcine
`• <0 0005%
`, .
`• •
`Thyrocalcitonin; Cys-Ser-Asn-Leu-
`T 0158
`Chloride (CQ.
`• • _ <0.05%
`. .
`- . . . . • . .
`~ Ser-Thr-Cys-Val-Leu-Ser-Ala-Tyr-Trp-Arg-Asn-leu-
`SO,. .
`, •
`. , , •••• • • . • . .
`<0 05%
`~,;,.;,,lum (Nl-4), ... ·. •. •. '. '. ·. '. •. •. ' ..• • <.O,~oi~~
`Asn-Asn-Phe-His-Arg-Phe-Ser-Gly-Met-Gly-Phe-Gly-
`Pro-Glu-Thr-Pro-NH, [Disulfide Bridge: 1-7]
`Cu
`. •..•.••.••• , • •
`<0.0005%
`fe.
`. ..• , .•...•... <0.0005%
`[72327-44-7] C1s9H232N4eO4sSa FW 3604
`min. 97% (HPLC)
`K . • .•. ••• _ • • •
`• , , , , • • • •
`• .. <0 01%
`Hypocalcemic hormone produced by the parafollicu-
`Mg.
`. .
`• • .
`• ... , . . . . . . • . . . . . . <0.1 %
`lar C cells of the thyroid or by the ultimobranchial
`N.:i. • •
`• . •
`• • • • • .
`• , , , • , • .
`<0 05%
`Pb. ,
`bodies of nonmammalian vertebrates . Decreases
`• •
`• •
`<0 001 %
`Zn, · ,. · • • · · · · • • · · · • · ·
`blood calcium and phosphate due to inhibition of
`<O.OOl %
`Calcium Activated Neutral Proll?ose See- Calpain II Page 363
`resorption by osteoblasts and osteocytes.
`Calcium-Binding Protein Vitamin 0.1 mg
`A 32 amino acid polypeptide, 8 of which are
`c 1540 D-induced
`0.5 mg
`conserved across all species.
`Ref.: 1. Tenenhouse, A., et al, Proc. Nat. Acad. Sci. USA 53, ~ from bovine mucosa
`
`habetical List of Products
`-- -
`
`www.sigma-aldrich.com
`
`Cale
`
`100 µl
`
`267.80
`
`Monoclonal Anti-Calcitonin
`Gene-Related Peptide
`antibody produced in mouse
`Clone CDS, Purified immunoglobulin, Buffered
`aqueous solution
`lmmunogen: peptide corresponding to the (-terminal
`of rat c,-calcitonin gene-related peptite (CGRP).
`Solution at approximately 100 µg/ml in 20 mM
`sodium phosphate buffer containing 0.01 % sodium
`azide.
`Species reactivity: human, guinea pig
`Application(s)
`Indirect immunofluorescence. • •
`incubation at 4°C
`lmmunohistochemistry (formalin-fixed, paraffin-embedded
`sections)
`1 '200-1 :1,000 using ovenight incubation at 4°(
`and sections that have bt,len protease-digested or processed by
`high temperature antigen retrieval
`suitable
`lmmunocytochemistry,
`Rel.: 1. Amara, S.G., et aL, Sc,cnce 229, 1094-1097 (1985)
`100 µL
`
`: 9487
`~
`RY ICE
`~
`
`_
`• 1 :500 usrng overnight
`
`250.00
`
`: 7113
`~
`lRY ICE
`~
`
`C 2806
`
`O 5 µg/ml using rat a-CGRP
`• suitable
`•• suitable
`•• suitable
`50.50
`168,50
`294.00
`
`70,90
`155.00
`260,00
`
`0.1 mg
`1 mg
`
`81.Z~
`405,0
`
`Monoclonal Anti-Calcitonin
`Gene-Related Peptide
`antibody produced in mouse
`approx. 2 mg/ml, Clone 4901, Purified immuno(cid:173)
`globulin, Buffered aqueous solution
`lmmunogen: rat a-CGRP peptide. The epitope
`recognized by the antibody resides within the
`(-terminal ten amino acids of rat a-CGRP,
`Cross-reacts with human and dog a- and P-CGRP.
`Solution in 0.01 M phosphate buffered saline, pH 7.4,
`containing 15 mM sodium azide.
`Species reactivity: rat
`App/ication(s)
`Indirect ELISA
`Rad10Jmmunoassay
`lmmunocytochemistry_
`Neutralization
`Calcitonin Gene Related Peptide 0.1 mg
`0.5 mg
`fragment 8-37 human
`a-CGRP 8-37; FBHuman; Val-Thr-
`1 mg
`His-Arg-leu-Ala-Gly-Leu-Leu-Ser(cid:173)
`Arg-Ser-Gly-Gly-Val-Val-Lys-Asn-Asn-Phe-Val-Pro(cid:173)
`Thr-Asn-Val-Gly-Ser-Lys-Ala-Phe-NH2
`[779977-68-7] CmH2aoN44O39 FW 3125
`min. 97% (HPLC), powder
`Selective competitive antagonist at CGRP receptors
`but not at calcitonin receptors .
`Peptide content approx. 70%
`Ref.: 1. Chiba, T., et al., Calcitomn gene-related peptide
`receptor antagonist human CGRP-(8-37) Am. J Physiof. 256,
`E331 (1989)
`2. Han, S_P., et al., Inhibition of periarterial nerve stimulation(cid:173)
`induced vasodilation of the mesenteric arterial bed by CGRP (8-
`37) and CGRP receptor desensitization Biochem. Biophys. Res
`Comm 168, 786-791 (1990)
`3, Escott, K J., and Brain, S,D , Effect of a ca!citonin ~ene~
`related peptide antagonist (CGRPB-37) on skin vasodilatat1on
`and oedema induced by stimulation of the rat saphenous nerve
`Br. 1. Pharmac<il 110. 777..-776 (1993)
`Calcitonin Gene Related Peptide 0.1 mg
`c 0167
`250 µg
`human
`~ CGRP-I; c,-CGRP; Ala-Cys-Asp-
`0,5 mg
`Thr-Ala-Thr-Cys-Val-Thr-His-Arg(cid:173)
`leu-Ala-Gly-Leu-Leu-Ser-Arg-Ser-Gly-Gly-Val-Val-Lys(cid:173)
`Asn-Asn-Phe-Val-Pro-Thr-Asn-Val-Gly-Ser-Lys-Ala(cid:173)
`Phe-NH2) [Disulfide Bridge: 27]
`[90954-53-3] C16aH261Ns1O49S2 FW 3789
`min. 95% (HPLC), powder
`Potem, long-lasting vasodilator; activation of CGRP
`receptors on pancleatic.P-cells increases plasma levels
`es.
`of ancrealic e
`p-Calcitonin Gene Related Pep-
`C 1044
`tide human
`~ p-CGRP; CGRP-11; Ala-Cys-Asn(cid:173)
`Thr-Ala-Th r•Cys-Val-Thr•His-Arg-Leu-Ala-Gly-Leu(cid:173)
`Leu-Ser-Arg-Ser-Gly-Gly-Met-Val-Lys-Ser-Asn-Phe-
`
`O. 1 mg
`
`29.80
`
`, •
`
`145, 1 O
`567 00
`
`1!r~1
`
`~~;) H B., et al., 1. Biol. Chem , 2454, 4232 (1970)
`[57607-43-9]
`~
`3. Schlueter, et al , Endocrinology 81, 854 (1967)
`lyoohilized powder
`___ .z4.!..!F~~•~leyir.•.!;J.~R::e·• .!:.• t~•~l.,!..!E:'..'.ndac=MO/oq=":::l'-Y-"123~, .:.:15:.::9.!.Cl:.:938:!.) ___ I Calcium bis(dihydrogenphosphate) monohydrate See Calcium
`50 µg
`42 ,20 phosphate monobasic Page 357
`Calcitonin rat
`Thyrocalcitonin; Cys-Gly-Asn-
`250 µg
`153_00 ~:;~~;tcalmodulin-Activated Protein Phosphatase See: Calcineurin
`T 0283
`~ leu-Ser-Thr-Cys-Met-Leu-Gly-
`1 mg
`337.50 calcium/calmodulin-dependent protein kinase 11-6 fragment 345-358
`Thr-Tyr-Thr-Gln-Asp-Leu-Asn-
`See Protein Kinase Related J>eo1idcsP,= 171 8
`L ys-Phe-H is-Th r-Phe-Pro-G In-Th r-Ser-I le-G ly-Val-G ly(cid:173)
`Ala-Pro-N H2 [Disulfide Bridge: 1-7]
`I 11718-25-5] c,.sH22aN4oO,6Sa FW 3399
`min. 95% (HPLC), powder
`Hypocalcemic hormone produced by the parafollicu(cid:173)
`lar C cells of the thyroid or by the ultimobranchial
`
`Calcium carbide
`27,029-6 [75•20-71 c,ca FW 64. 1 o
`Aldrich
`- 80%, pieces, tech., thickness
`ca. 8 mm
`•
`• •••••
`Density.
`R: 15 5: 8-43
`
`25 g
`500 g
`2 kg
`
`19.70
`21.70
`27.80
`
`2 22 g/ml (lit I
`
`• Larger quantities - see page 16
`
`To place an order call 800-325-301 0 • www.sigma-aldrich .com/order
`
`351
`
`

`

`C 4830
`
`25 .70
`84.80
`
`• -
`
`1 l2.~
`:?~.~O
`
`. .
`
`USP
`
`C 6763
`C 5929
`
`C 7981
`
`Calcium carbonate
`subunit. J. Biol. Chem. 268, 19451 (1993)
`[471 _34.1] CaCO, FW 100.1
`4 Hell, J.W., et al, Phosphorylation of P,O!syi,optl( a
`postsynapt1c calcium channels by cAMP·d~eti\ nd
`ltl!W<! in hlppocampal nellrons. EMBOJ. 14, 3036-"3 P(l'ltii
`~- ?7(38;41.
`_S: ?6;39,
`5. Wcs!enbroek. R.E. el al .. lmmuno(hemic.ill lo.kn ~l1~
`SigmaUltra, min. 99.0%
`100 g
`and sub«!llular disuibutlon of th~ alpha IA Wbo,,i1sb _
`101elubla m\ltter. . . . . . . . . <0.1 % 500 g
`calc,um channels. J. Neurosci. 1S, 6403-6418Q2gs) of bl-,
`Phosphorus (Pl
`<0.0005%
`001
`Chlotide (CQ. ·
`Anti-Calcium Channel (a ,A Sub- 0.05 rnl
`%
`' <O
`' •
`• •• : ~ ~: • ~ ~ •• ~ : • • • <~o()~~~t: C 1353
`4
`0.2 rnL
`unit) (P/Q-type of Voltage-
`~
`•
`• •
`•
`:
`, ..... <0 05% ~ gated ca2• Channel)
`Ammonium {NH.al
`, .. , • • •
`•
`antibody produced in rabbit
`Ba ... .•••••• . •. , • • • • • . • • •
`, <0 005%
`, , .. <(cid:143) .ooo5%
`Affinity Isolated antibody, lyophllized Po
`cu , • •
`•
`, • • .
`• .
`• • • <0 ooo5%
`de,
`lmmunogen: synthelic peptide corr~pond]l'\g "'
`Fe. . . . . . • •
`•
`• • • • • • • • • •
`0
`amino adds 865-881 of the a ,,, subunit of ratt .
`1
`<
`oos%
`K.
`• • , , • , • • • • • •
`• • • •
`•
`voltage-gated calcium channel (VGCC. CNA1) c1oJ~
`~ - .' .' ·::: .': .':: _-::: ·::::::: · :~-~~;~
`additional N•terminal lysine and tyrosine) conJ~g I
`, • • • . • • • • . • • • • • • • • • . . <0 001 %
`Pb
`alt<j
`toKLH 1•
`., ••••·••.
`. .
`<0.1 %
`Sr
`~n . • . · . . . . · .
`.. : .. . . •. , ,
`, • • .• • . <9.o_oo2o/1
`By immunoblotting, the antibody recognizes the
`!11i.n .. 9~.q%_ . . . . . , .. , _5qo .9 •• 19,8q
`subunit, both the major 190 kDa and the minor u,A
`insect cell culture tested, ap-
`100 g
`23 ,80
`210 kDa form of VGC C.
`lyoptiilized at approximately 0. 3 mg/ml from
`_5qo .9 . . (i6,6~
`pr!)X_. ~9o/, .
`phosphate buffered saline, pH 7.4, coniainlng· 1,;,
`90
`52
`bovine serum albumin, 5% sucrose a~d 0.02S% 0
`lOO g
`·
`_5qo .9 • • 1 ?5,oq
`sodium azlde
`50 g
`13.40
`Antigen (major) mol wt 190 kDa
`Antigen (minor) mol wt 210 kDa
`250 g
`39.30
`• . ] k_g • • 113,6q
`Species reactivity: rat, mouse
`100 g
`25.20
`Application(s)
`1 l(I)
`lndjn>ct immunobloul119 ((heml1urn1nesmi1)
`57 3 0
`500 g
`- SOl1!$i
`lmmunop,edplmion, ·
`so.01 % 6 x 500 g
`· ·
`·
`·
`· · ·
`264.60
`. >lii.,Q,.
`Immunocyto<hemls1ry. • • • . . •
`. . • . .
`Ref.: 1. Storr, T,V.B., et al .. Prima,y srructuro. of a calM
`1 kg
`channel 1ha1 Is highly c,,p, .. sed In I~• rat rnebellum_ ~
`2.5 kg
`MJI. Aoo. 5cl USA 88, 5621-5625 (1991)
`2. Wostenbrwk, R.E., el al , Jrnmunoc""mitail lnoentilicat,on
`andsubccllular distribution of I~• alpiia tA kibunits of brain
`
`'
`
`-
`
`so 00
`
`2
`meqlg
`
`0
`
`•
`
`•
`
`•
`
`•
`
`•
`
`•
`
`0.2 ml
`
`365,70
`
`8-
`
`~••vv metals.
`Mg
`NH,
`
`• · •
`. • , . , • •
`•
`• , , , , • • • • • • • • • • • • •
`
`•
`
`· •
`•
`
`I
`I
`I V
`
`iii u
`
`21061
`fluka
`
`23,921-6
`Aldrich
`
`BioChemika Ultra, precipi(cid:173)
`tated, ~99.0% (KT)
`. . • .
`. • . .
`. • • . ,
`>99 O'¾ ACS re
`d
`0
`pow er, -
`·
`!l?A~nditl uc1
`1
`1n-.
`...,
`•
`till,
`vmer-solubl
`95.70
`Base,
`•
`239.40
`. . . ~0.~0~":
`:111:'t':pttS,
`, so 01 %
`~t ·, · · · · ·, ·. ·. ·. ·. ·. ·, ·. ·. ·. ·. ·. ·. ·. ·. ·. ·. ·. ·. ~2
`~0'.~a(t~;
`• so OOl 5%
`~a~~k: r:~~~ ai:.~~~':'~c~:~:~f~~)i~c~t: :)and
`. ••.•• , . •• . , • • • • • • •
`F'. •
`dlf erentlal phospharylatlon of _ahematlve!y spliced forms of ihe
`·
`· sO .OI %
`• · • · •
`• • · • · · • • • • · ·
`So/·,
`· • so.oo5
`alpha IA subuintof brain calclum channel<. J, Biol. Chem, 270,
`Ba •• ••••• , • • • • • · • • • • • • • • ·
`%
`· · so 003%
`2123~-21242 (1995)
`Fe. , , ,
`, • , •
`• • • • • • · • • •
`• ,':::::: ·::: .':: ..• s~oo~;~ I - - -A- n-"t"'i-""ca::.lc:c.ci:.:u""m"-C"'-h=ac.:cn'---n-el_(_a-,
`S_u_b_· _ O_-o-5 _m_l - -1-12-,00
`so .o2% c 1478 unit) (N-tlpe of Voltage-
`• s0,003% ~ gated Ca • Channel)
`~ra. · · · · • · • · • · · · • • · • • • · · · · · ·::. !~:; ~:
`antibody produced in rabbit
`Affinity isolated antibody, Lyophilized powder
`lmmunogen: synthetic peptide corresponding to
`amino acids 851-867 of the a 18 subunit of rat brain
`voltage-gated calcium channel (VGCC, CNB1), with
`additional N-terminal lysine and tyrosine, conjugated
`to KlH' _
`By immunoblotting, the antibody recognizes both the
`low M.W. and the high M .W . forms of the a
`subunit of VGCC.
`Lyophilized at approximately 0,3 mg/ml from
`phosphate buffered saline, pH 7.4, containing 1%
`bovine serum albumin, 5% sucrose and 0.025%
`sodium azide
`Antigen mol wt 21 o kDa (low)
`Antigen mol wt 240 kDa (high)
`Species reactivity: rat, mouse
`Appiication(s)
`1:200·1 61JO
`Indirect immunoblotting (chemiluminescent)
`· · .·: ~%~
`:~~~~~~~ii;:~ii~~~ · • _- • .' _- · _-. • .
`Ref.: 1. Westenbroek, R,E,, Biochemical prQp,,!lies and
`subcellular distribution of an N-type caldum {han~.i olplta I
`subunit Neuron 9. 1099 119921
`Anti-Calcium Channel (a,c Sub- 0.05 ml
`unit} (L ... ~pe of Voltage-
`binding region within the alpha 1 subunit of skeletal muscle ~ gated Ca • Channel)
`d r
`antibody produced in rabbit
`Ca'' channels Proc. Nat, Acad Sci. USA 87, 9108-9112 (1990)
`Affinity isolated antibody, Lyophilized pow e
`2. Ahlijanian, M,K, et al, Phosphorylation of an a_lpha 1-like
`lmmunogen: synthetic peptide corresponding lObral!t
`subunit of an omega-conotoxin-sens,tive brain calc,um channel
`amino acids 818-835 of the 0:1c ~ubunlt or rat
`·Jll
`by CAMP-dependent protein kinase and protein kinase J. Biol
`voltage-gated calcium channel (VGCC. CNC1H11'!!1
`Chem. 266, 20192.20197 (1991)
`additional N-term nal lysine and tyrosine) con1ugi11
`~/ · ~~ ~!ua;;n~:r:~;:sn~a:~;~:Pc~~~f~~i~~a~n~~~l;i~= 1
`
`0,05 ml
`O 2 ml
`
`112.00
`365.70
`
`Anti-Calcium Channel (a, Sub-
`C 1103 unit), Pan
`~ antibody produced in rabbit
`Affinity isolated antibody, Lyophilized powder
`lmmunogen: synthetic peptide [(c)DNFD YLTRD
`WSllG PHHlD] corresponding to amino acids 1506-
`1524 of the a,s subunit of rat skeletal muscle
`voltage-gated calcium channel (VGCC, CP15) (Ac-
`cession P22002) with additional N-terminal cyste1ne,
`conjugated to MBS-KlH
`By immunoblotting, the antibody recognizes all types
`of the a, subunits. The epitope recognized by this
`antibody is masked by aZ and 3 chains; therefore the
`antibody binds only after subunit dissociation using
`Triton X-100 or other detergents.
`lyophilized at approximately 0.3 mg/ml from
`phosphate buffered saline, pH 7.4, containing 1 %
`bovine serum albumin, 5% sucrose and 0.025%
`sodium azide
`Species reactivity: rat, mouse
`. , , • . .
`Air,;!~~~;~::/pitat,on, ,
`•
`Indirect immunoblotting (chemiluminescent'
`
`R~~-~~-ni~r:~~;.~:~t~ al., ldentificatio~ of a phen; lalkyl~~:i~~ C 1603
`
`suitable
`•
`. t :200-1 :600
`
`18
`
`0.2 ml
`
`t~~11
`
`352
`
`For technical service call 800-325-5832 • www.sigma-aldrich.com/techinfo
`
`

`

`Orcler/Custome~ Ser.vice
`800-325-30i1 0 or:
`sigma-alclridi .com/orcler:
`
`General Information 800.:52i1-8956 or:
`sigma=alclridi .com
`
`